Market closedNon-fractional

Lyell Immunopharma/LYEL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Lyell Immunopharma

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Ticker

LYEL

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

South San Francisco, United States

Employees

224
Website
lyell.com

LYEL Metrics

BasicAdvanced
$385M
Market cap
-
P/E ratio
-$0.91
EPS
-0.40
Beta
-
Dividend rate
$385M
-0.4
16.511
16.267
9.145
10.25
-18.93%
-32.93%
5,613.383
0.64
0.64
-2.37
-99.92%
23.66%
-80.34%
-61.37%

What the Analysts think about LYEL

Analyst Ratings

Majority rating from 4 analysts.
Buy

LYEL Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$61M
14.56%
Profit margin
0.00%
NaN%

LYEL Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 14.29%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.26
-$0.20
-$0.20
-$0.24
-
Expected
-$0.27
-$0.25
-$0.23
-$0.21
-$0.19
Surprise
-4.88%
-20.00%
-12.28%
14.29%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Lyell Immunopharma stock?

Lyell Immunopharma (LYEL) has a market cap of $385M as of July 06, 2024.

What is the P/E ratio for Lyell Immunopharma stock?

The price to earnings (P/E) ratio for Lyell Immunopharma (LYEL) stock is 0 as of July 06, 2024.

Does Lyell Immunopharma stock pay dividends?

No, Lyell Immunopharma (LYEL) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Lyell Immunopharma dividend payment date?

Lyell Immunopharma (LYEL) stock does not pay dividends to its shareholders.

What is the beta indicator for Lyell Immunopharma?

Lyell Immunopharma (LYEL) has a beta rating of -0.4. This means that it has an inverse relation to market volatility.

Buy or sell Lyell Immunopharma stock

Buy or sell Lyell Immunopharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing